Blood Biomarkers for Alzheimer's Disease and Cognitive Status
Author Information
Author(s): Sullivan Kevin, Blackshear Chad, Pike James, Walker Keenan, Windham B Gwen, Mosley Thomas, Griswold Michael, Palta Priya
Primary Institution: University of Mississippi Medical Center
Hypothesis
Blood-based biomarkers can help monitor and detect individuals at high risk for cognitive decline.
Conclusion
Blood biomarkers are associated with an increased risk of dementia and mild cognitive impairment in older adults.
Supporting Evidence
- AB42 was associated with a reduced risk of dementia.
- ptau-181 was linked to an increased risk of dementia.
- GFAP showed a significant association with dementia risk.
- NFL was also associated with an increased risk of dementia.
- AB42 was associated with a reduced risk of mild cognitive impairment.
- ptau-181 indicated an increased risk of mild cognitive impairment.
- GFAP showed a potential link to mild cognitive impairment.
- NFL was associated with an increased risk of mild cognitive impairment.
Takeaway
Scientists are studying blood tests to see if they can tell if someone might get Alzheimer's disease or other memory problems.
Methodology
Blood biomarkers were measured in plasma using ultrasensitive assays, and cognitive outcomes were assessed through various methods over a median follow-up of 6.5 years.
Participant Demographics
Mean age 76 years, 61% female, 31% Black.
Statistical Information
Confidence Interval
95% CI: 0.40,0.83; 95% CI: 1.74,3.30; 95% CI: 1.22,4.53; 95% CI: 1.29, 2.94; 95% CI: 0.62,0.95; 95% CI: 1.31,1.99; 95% CI: 0.99,1.56; 95% CI: 1.11, 1.87
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website